Hemochromatosis - Pipeline Insight, 2021

SKU ID :DEL-17687650 | Published Date: 15-Mar-2021 | No. of pages: 60
Introduction Executive Summary Hemochromatosis: Overview • Causes • Mechanism of Action • Signs and Symptoms • Diagnosis • Disease Management Pipeline Therapeutics • Comparative Analysis Therapeutic Assessment • Assessment by Product Type • Assessment by Stage and Product Type • Assessment by Route of Administration • Assessment by Stage and Route of Administration • Assessment by Molecule Type • Assessment by Stage and Molecule Type Hemochromatosis – DelveInsight’s Analytical Perspective In-depth Commercial Assessment • Hemochromatosis companies’ collaborations, Licensing, Acquisition -Deal Value Trends Hemochromatosis Collaboration Deals • Company-Company Collaborations (Licensing / Partnering) Analysis • Company-University Collaborations (Licensing / Partnering) Analysis Late Stage Products (Phase III) • Comparative Analysis Drug name: Company name • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Mid Stage Products (Phase II) • Comparative Analysis PTG-300: Protagonist Therapeutics • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Early Stage Products (Phase I) • Comparative Analysis Drug name: Company name • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Preclinical and Discovery Stage Products • Comparative Analysis Matriptase-2 inhibitor: Disc Medicine • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Inactive Products • Comparative Analysis Hemochromatosis Key Companies Hemochromatosis Key Products Hemochromatosis- Unmet Needs Hemochromatosis- Market Drivers and Barriers Hemochromatosis- Future Perspectives and Conclusion Hemochromatosis Analyst Views Hemochromatosis Key Companies Appendix
Table 1 Total Products for Hemochromatosis Table 2 Late Stage Products Table 3 Mid Stage Products Table 4 Early Stage Products Table 5 Pre-clinical & Discovery Stage Products Table 6 Assessment by Product Type Table 7 Assessment by Stage and Product Type Table 8 Assessment by Route of Administration Table 9 Assessment by Stage and Route of Administration Table 10 Assessment by Molecule Type Table 11 Assessment by Stage and Molecule Type Table 12 Inactive Products
• Protagonist Therapeutics • Disc Medicine • Silence Therapeutics • La Jolla Pharmaceutical Company
  • PRICE
  • $1500
    $4500

Our Clients